Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in January

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 31st total of 232,000 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average trading volume of 322,600 shares, the short-interest ratio is currently 1.7 days.

Aadi Bioscience Price Performance

NASDAQ AADI opened at $2.89 on Thursday. The company’s 50 day simple moving average is $2.81 and its two-hundred day simple moving average is $2.16. The stock has a market capitalization of $71.24 million, a PE ratio of -1.27 and a beta of 0.65. Aadi Bioscience has a 1 year low of $1.21 and a 1 year high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.46). Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%. The company had revenue of $7.21 million for the quarter, compared to the consensus estimate of $6.55 million. During the same quarter last year, the business posted ($0.60) earnings per share. On average, research analysts anticipate that Aadi Bioscience will post -2.04 EPS for the current year.

Institutional Trading of Aadi Bioscience

A number of large investors have recently modified their holdings of AADI. XTX Topco Ltd bought a new position in shares of Aadi Bioscience in the third quarter worth approximately $32,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Aadi Bioscience in the 2nd quarter worth approximately $37,000. Peapod Lane Capital LLC purchased a new position in Aadi Bioscience in the 4th quarter worth approximately $1,397,000. Finally, BML Capital Management LLC bought a new position in shares of Aadi Bioscience in the 3rd quarter worth $4,120,000. Institutional investors own 52.08% of the company’s stock.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.